LungÕ 2026 – Virtual Global Congress on Lung Oncology
ASTRIDE Bridges the Gap: Serplulimab Matches 32% Two-Year Survival in U.S. Patients with Small Cell Lung Cancer
Daniel Malarek and a Wish for Oncology: A Future Where Breakthroughs Reach Every Patient
Expert Discussion at COGC 2026: The Right First Investments in Precision Oncology
London Global Cancer Week 2026: Highlights From November 2–4
From TAILORx to OPTIMA: Genomic Testing Expands Chemotherapy De-escalation in Higher-Risk HR-Positive Breast Cancer
BeOne Medicines’ Zanubrutinib Combination Gains FDA Priority Review for First-Line Mantle Cell Lymphoma
Perioperative Ivonescimab Shows Promising Pathological Responses in Resectable NSCLC: Phase II Trial Reports 70.1% MPR and 50.7% pCR
OncoDaily IO is the dedicated immuno-oncology platform of OncoDaily, focused on the rapidly evolving science and clinical practice of cancer immunotherapy. It covers the full spectrum of immuno-oncology, including immune checkpoint blockade, cellular therapies, therapeutic cancer vaccines, antibody-based strategies, oncolytic viruses, next-generation immunomodulatory approaches, tumor microenvironment, immune biomarkers, neoantigens, treatment response and resistance, and personalized immunotherapy. Through OncoDaily IO, readers can follow the latest clinical trials, pivotal studies, translational research, regulatory decisions, emerging therapies, major congress highlights, and interviews with leading international experts advancing cancer prevention, control, and treatment through immunotherapy.
